Illumina Shares Lower Amid Action From Multiple Sell-Side Analysts


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Despite action from multiple sell-side analysts, shares of Illumina, Inc. (NASDAQ: ILMN) are trending downward on the day.

Illumina was recently seen trading down 5.33 percent at $168.10 from a Wednesday close around $177.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Thus far into Thursday's trading, the company's shares reached a high of 173.75 and a low of 167.12.

Deutsche Bank

Deutsche Bank initiated with a Hold with a price target of $192.00 on Wednesday.

"ILMN shares recovered strongly into year-end following steep declines in 2H15 due to overly high expectations, growing fears of increasing competition, and a negative guidance revision," the firm noted.

Wells Fargo

Wells Fargo downgraded Illumina from Outperform to Market Perform.


Want Private Access to Benzinga Analyst?

Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.


The firm noted the following in a research note released Thursday, "The probability that Illumina will announce a product launch big enough to re-accelerate revenue growth in 2016 is low."

AvondalePartners

Avondale initiated coverage of the issue with a Market Perform rating with a $175.00 price target.

The research firm sees Illumina as a dominate player in the next-generation sequencing market, however the firm remains hesitant of its "hefty" valuation. Avondale noted being "skeptical" of Illumina's total market estimate.

Cowen And Company

Cowen and Company raised its price target of the company to $215 on Thursday.

In October, the firm reiterated an outperform rating and issued a $220.00 target price (lowered from $300.00) on shares of Illumina in a research report.

Barclays

Lastly, Barclays raised its target from $170 to $175, maintaining an Equal Weight rating.Image Credit: Public Domain

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Posted In: BiotechLong IdeasNewsDowngradesPrice TargetInitiationReiterationAnalyst RatingsMoversTrading IdeasGeneralAvondale PartnersBarclaysCowen and CompanyDeutsche BankWells Fargo